News & Analysis on Clinical Trial Services & Contract Research And Development
Overcapacity remains the main issue affecting the European market for active pharmaceutical ingredients, with lack of capability differentiation and competition from low-cost manufacturers also holding back growth in the sector.
Astrazeneca and Cambridge Antibody Technology (CAT) have entered into an alliance to jointly discover and develop human monoclonal antibody therapeutics, principally in the field of inflammatory disorders, including respiratory diseases. The...
Scientists have identified a new, longer species of the amyloid b-peptide that has the potential to be a new target for the treatment of Alzheimer's disease The discovery serves as a basis for treating one of the characteristic features of Alzheimer's...
Biotechnology company Proteus has been issued with a new US patent that details the functional screening of candidate active compounds using in vitro protein expression. The granting of the patent corresponds to the company's proprietary technology...
Research that could eventually lead to gene therapy treatment options for patients with Parkinson's disease has been published this week, which could bring hope to more than 1 million Americans each year who suffer from this neurodegenerative disorder.
Manchester, UK-based Avecia has sold off its Special Drug Mixtures subsidiary to Copperhead Chemical of the US.
The UK Packaging and Industrial Films Association (PIFA) is warning buyers of plastic film products to expect further price increases as producers and converters are forced to look for recovery of exceptional rising raw material costs. The news comes...
Affymetrix has extended the range of custom microarrays by launching a host of prokaryotic array designs, which offer scientists an affordable tool to conduct whole-genome expression studies on a wide range of pathogenic organisms.
Flint Ink North America has announced a price increase for packaging ink products ranging from 5 to 7 per cent depending on ink type. The increase, effective 1 December 2004, comes in response to the rising costs of transportation, energy, and raw...
Japan's Ajinomoto has developed a revolutionary enzymatic method to manufacture peptides that could dramatically cut the cost of producing this growing class of therapeutic agents.
German chemical and pharmaceutical company Merck KGaA has sold off a manufacturing facility in France in a move aimed at consolidating its global production infrastructure.